Povorcitinib - Incyte Corporation
Alternative Names: INCB-054707; INCB-54707Latest Information Update: 26 Apr 2024
At a glance
- Originator Incyte Corporation
- Class Anti-inflammatories; Antiasthmatics; Azetidines; Benzamides; Fluorinated hydrocarbons; Nitriles; Pyrazoles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hidradenitis suppurativa; Vitiligo
- Phase II Asthma; Chronic urticaria; Prurigo nodularis
- Phase I Skin disorders
Most Recent Events
- 24 Apr 2024 Incyte Corporation plans a phase I drug interaction trial in healthy adult females in USA (PO) (NCT06380205)
- 31 Mar 2024 Povorcitinib licensed to China Medical System in China, Hong Kong, Macau, Taiwan and South East Asia for the treatment of Vitiligo, Hidradenitis suppurativa, Prurigo nodularis, Asthma, Chronic urticaria
- 10 Mar 2024 Efficacy and adverse events data from a phase II trial in Prurigo nodularis released by Incyte Corporation